P/E ratio for Amphastar Pharmaceuticals (AMPH)
P/E ratio as of April 2024 (TTM): 19.5
According to Amphastar Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.481. At the end of 2022 the company had a P/E ratio of 15.0.
P/E ratio history for Amphastar Pharmaceuticals from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 15.0 | -16.36% |
| 2021 | 17.9 | -96.8% |
| 2020 | 560 | 2920.67% |
| 2019 | 18.5 | -112.12% |
| 2018 | -153 | -174.63% |
| 2017 | 205 | 167.27% |
| 2016 | 76.8 | -132.36% |
| 2015 | -237 | 405.18% |
| 2014 | -46.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Tonix Pharmaceuticals TNXP | -0.0114 | -100.06% | 🇺🇸 USA |
 SCYNEXIS SCYX | 1.65 | -91.54% | 🇺🇸 USA |
 Marinus Pharmaceuticals MRNS | -13.1 | -167.20% | 🇺🇸 USA |
 Agile Therapeutics
AGRX | -0.0094 | -100.05% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.